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Objective: To determine whether sagittal abdominal diameter (SAD) is associated with the 
metabolic syndrome independently of visceral fat area (VFA) and waist circumference (WC).
Methods: Forty-three high-risk vascular patients were evaluated for metabolic syndrome criteria 
and underwent magnetic resonance imaging (MRI) to quantify SAD and VFA at the L4–L5 disc.
Comparisons: 1. Baseline differences in patients with and without the metabolic syndrome 
2. Forward binary logistic regression analysis of predictors of the metabolic syndrome with 
SAD, VFA and WC as independents 3. Correlates of SAD.
Results: Patients with metabolic syndrome had greater SAD, VFA and WC than patients 
without the metabolic syndrome (P , 0.01). Of SAD, VFA and WC, only SAD was associated 
with metabolic syndrome on forward binary logistic regression; beta 0.68, Wald’s statistic 10.8 
(P = 0.001) and c-statistic 0.89 (P , 0.001). A . 22.7 cm SAD threshold identified metabolic 
syndrome with a 91% sensitivity and 80% specificity. SAD correlated with waist circumference 
(r = 0.918), high-density lipoprotein-cholesterol (r = –0.363), triglyceride (r = 0.401), fasting 
glucose (r = 0.428) and the QUICK index of insulin sensitivity (r = –0.667) (all P , 0.05).
Conclusions: MRI-measured SAD is associated with the metabolic syndrome and renders the 
current gold standard of VFA redundant. This measure of obesity-related cardiovascular risk 
requires validation and evaluation in a prospective cohort.
Keywords: obesity, insulin resistance, waist circumference, metabolic syndrome, sagittal 
abdominal diameter, visceral fat area
Introduction
The increased risk of cardiovascular events associated with obesity is driven by the 
accumulation of visceral fat and insulin resistance.1–5 Waist circumference (WC) is 
typically used in clinical practice to both quantify abdominal obesity and to make the 
diagnosis of the metabolic syndrome. In patients with established vascular disease, as 
in healthy patients, the diagnostic label of ‘metabolic syndrome’ portends an increased 
risk of cardiovascular events and therefore carries clinical significance.6–9 While several 
reports have suggested that the anteroposterior diameter of the abdomen, the sagittal 
abdominal diameter (SAD), is a superior correlate of metabolic syndrome criteria 
and insulin resistance than waist circumference, there has been little incorporation of 
this measure into routine clinical practice.10–13 SAD has recently been suggested to 
be a superior predictor of the metabolic syndrome than visceral fat area (VFA) in a 
single report.14 VFA, measured at the umbilicus, is the current gold standard for the 
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determination of obesity-related cardiovascular risk and is 
a determinant of metabolic risk factors and the metabolic 
syndrome after correction for body mass index (BMI) and 
WC.4,15 Further, VFA has been independently linked to the 
development of coronary artery disease.16 Hence, the finding 
that SAD is a superior predictor of the metabolic syndrome 
than VFA potentially carries important implications. Firstly, 
SAD may be measured with the Holtain–Kahn abdominal 
caliper without requiring any imaging, with its associated 
costs. Secondly, while commercial software is available to 
automate the process of quantifying fat areas from imaging, 
the process remains time-consuming and requires human 
input for analysis of appropriate images. Hence we sought 
to reproduce the finding that SAD is a superior predictor 
of the metabolic syndrome than VFA and to also compare this 
to WC. Further, we sought to investigate the correlation of 
SAD with the individual criteria of the metabolic syndrome 
and insulin sensitivity on a continuous scale.
Methods
study population
We recruited patients with coronary artery disease (CAD), 
ischemic stroke, or CAD risk-equivalents. Eligible patients 
had to have at least one of the following: 1. CAD (positive 
angiogram or history of myocardial infarction) 2.  Peripheral 
vascular disease (ABI , 0.9 or history of lower limb 
 revascularization for atherosclerosis) 3. Abdominal aortic 
aneurysm 4. carotid atherosclerosis with .50% narrow-
ing 5. type II diabetes with age . 50 and 3 additional risk 
factors (male sex, albuminuria, hypertension, high-density 
lipoprotein-cholesterol [HDL-C] , 40 mg/dL, triglycerides 
[TG] . 150 mg/dL, low-density lipoprotein-cholesterol 
[LDL-C] . 100 mg/dL, current smoking, diabetes duration 
.20 years), or 6. Ischemic stroke.  Eligible patients were 
not taking lipid-modifying drugs. Study  participants were 
in a clinically stable condition and were recruited from the 
vascular surgery outpatient department at the Royal Brisbane 
and Women’s Hospital.
Patient data
Patient demographic information was collected  including age, 
sex, qualifying criterion, self-reported race,  current medica-
tions, cigarette smoking, blood pressure, anti-hypertensive 
medication use, height, weight, and waist circumference. 
Metabolic syndrome was defined as per the Adult Treatment 
Panel III (ATP III) criteria.17 Fasting blood samples were 
 analyzed for baseline lipids, glucose, and insulin. Fasting lipid 
profile and glucose were determined using standard  hospital 
methods. Insulins were measured by  chemilumnescent 
 immunoassay on a Beckman Coulter DxI800 (Beckman 
Coulter UK Ltd, London, UK) as per the manufacturer’s 
instructions. To determine insulin sensitivity, we used the 
quantitative insulin sensitivity check index (QUICK index) 
since this a superior linear correlate (r∼0.8–0.9) of the 
 reference  standard glucose clamp than the homeostasis model 
assessment (HOMA) model.18,19
MRi measurement of abdominal fat areas
MR imaging was performed with a Siemens Trio 3 T MRI 
system (Siemens AG, Erlangen, Germany) using standard 
array coils with the subject supine. Breath-hold FISP images 
were centered on the L4–L5 intervertebral disc using standard 
localizer images with the following parameters: TR = 4 ms, 
TE = 2 ms, number of slices = 12, slice thickness = 8 mm, 
image matrix 256 × 256, field-of-view = 500 × 500 mm. The 
4 slices that were best aligned with the L4–L5 disc (19, 20), 
were analyzed using the polygon region of interest in Escape 
medical viewer v3.2 to define visceral fat area (VFA) as 
described previously.20 Briefly, VFA was measured by fitting 
a spline curve to points on the border of the subcutaneous 
and visceral regions. Nonfat regions within the visceral 
region were also outlined with a spline fit and subtracted 
from the total visceral region. The SAD was measured at 
the L4–L5 disc by measuring the distance from the anterior 
part of the body to the posterior portion of the body using 
the caliper function on the software package. However, SAD 
can be measured using the Holtain–Kahn abdominal caliper 
without imaging.
statistical methods
The baseline characteristics of the included patients were 
summarized and the diagnosis of the metabolic syndrome 
as per ATP III criteria17 was determined for each patient. We 
compared patients with and without the metabolic syndrome 
for various metabolic parameters and imaging parameters. We 
compared the means of continuous variables with a two-tailed 
Student’s t-test for normally distributed variables, and with the 
 Mann–Whitney U test for non-normally distributed variables. 
 Categorical  variables were analyzed with the Chi-square test 
or Fisher’s exact test. We then used forward LR binary logistic 
 regression to identify independent predictors of patients having 
the diagnosis of the metabolic syndrome. Candidate variables 
selected for logistic regression were three  measures of obesity: 
VFA, SAD, and WC. Variables were only entered into the 
model if the P-value of the score statistic was less than the entry 
value of 0.05. Wald statistics and odds ratios were reported for 
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variables in the final model and the overall model was assessed 
with the c-statistic for predicting the metabolic syndrome. 
ROC curves were used to identify an optimal SAD cut-off for 
predicting the  metabolic syndrome with acceptable sensitivity 
and specificity. In order to determine correlates of SAD, we 
undertook  univariate correlation with the metabolic syndrome 
criteria and insulin sensitivity (the QUICK index) as indepen-
dents and SAD as the dependent variable. The QUICK index 
of insulin  sensitivity for each subject with insulin and glucose 
data was calculated as 1/[log (fasting insulin, µU/mL) + log 
(fasting glucose, mg/dL)].18 Variables that correlated with 
SAD with a Spearman’s P , 0.05 were subjected to  stepwise 
multivariate linear regression and the R2 change calculated 
with the addition of any variable to the model. To remove the 
influence of multicollinearity from the multiple regression 
model, variance-inflation factors (VIFs) were determined, 
and variables with a VIF . 4.0 were removed from the model. 
Residuals from the regression model were graphically exam-
ined. All analyses were done with statistics software (V. 16 
SPSS Inc., Chicago, IL, USA).
Ethics approval
This study is approved by the RBWH research ethics 
 committee (2005/006A) and all study participants gave 
informed consent.
Results
We enrolled 43 patients in this MRI study. Baseline 
 characteristics, including components of the metabolic 
syndrome, baseline lipid panel, insulin and QUICK index 
of insulin sensitivity are shown in Table 1. The differ-
ences between the patients with and without the metabolic 
syndrome are summarized in Table 2 and show expected 
differences in various metabolic parameters. Patients 
with metabolic syndrome had greater WC, SAD, and 
VFA compared to patients without the metabolic syn-
drome (P , 0.01). In order to determine which of these 
measures of obesity is most strongly associated with the 
metabolic syndrome, we subjected the outcome of meta-
bolic syndrome to binary logistic regression analysis with 
WC, SAD, and VFA as independents. On forward logistic 
regression, only SAD entered the model with no indepen-
dent contribution from waist circumference or VFA; beta 
0.68, Wald’s statistic 10.8, P = 0.001. The overall c-statistic 
for SAD in identifying the metabolic syndrome was 0.89 
(P , 0.001) and, in this sample, an SAD of . 22.7 cm 
identified the metabolic syndrome with 91% sensitivity 
and 80% specificity.
Table 1 characteristics of patients included in the analysis
Mean ± SD or n (%)
Age 70 ± 8
Males 35 (81)
Females 8 (19)
Race
 White 42 (98)
 non-White 1 (2)
Height (cm) 172 ± 10
Weight (kg) 79 ± 19
Body mass index 26 ± 5
Diabetic, n (%) 10 (23)
Metabolic syndrome (ATP iii), n (%) 22 (53)
Waist (cm) 101 ± 16
Visceral fat area (cm2) 203 ± 111
sagittal abdominal diameter (cm) 23.2 ± 4.0
Fasting glucose (mg/dl) 112 ± 40
HDL cholesterol (mg/dl) 44 ± 17
Triglycerides (mg/dl) 142 ± 74
systolic blood pressure (mmHg) 142 ± 19
Diastolic blood pressure (mmHg) 72 ± 9
Average number of ATP iii criteria 2.7 ± 1.5
Fasting insulin (mU/L) 7 ± 4
QUicK index 0.25 ± 0.03
Qualifying criteriona
 coronary artery disease 10 (24)
 Peripheral vascular disease 23 (55)
 carotid atherosclerosis .50% 12 (29)
 Abdominal aortic aneurysm 10 (24)
 ischemic stroke 8 (19)
 Diabetes 10 (24)
Notes: aPatients frequently had .1 inclusion criterion.
Abbreviations: ATP, Adult Treatment Panel; HDL, high-density lipoprotein; sD, 
standard deivation.
Despite the criticism of the label of metabolic syn-
drome as being no greater than a sum of risk factors, it 
remains a  clinically-useful label denoting an increased 
 cardiovascular risk.21 However, given evidence that insulin 
resistance drives the increased risk of cardiovascular events 
in obese individuals,22 we assessed the utility of an SAD 
of .22.7 cm in identifying insulin-resistant patients. We 
compared the QUICK index of insulin sensitivity in patients 
with an SAD of .22.7 cm and ,22.7 cm and found that 
patients with SAD .22.7 cm were significantly more insu-
lin resistant (lower QUICK index score) than those with an 
SAD ,22.7 cm, P = 0.01. Next, we sought to confirm the 
association between SAD and metabolic indicators of risk 
by correlating the SAD to each of the metabolic syndrome 
criteria and the QUICK index. The QUICK index and all 
the metabolic syndrome criteria, except for the hyperten-
sion criterion, were significant correlates of SAD as shown 
in Table 3. On stepwise multivariate analysis of the signifi-
cant  univariate correlates as independents and SAD as the 
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Table 3 Univariate correlates of sagittal abdominal diameter
Waist 
circumference
HDL 
cholesterol
Fasting 
triglyceride
Fasting glucose ATP III hypertension 
criterion
QUICK 
index
Spearman’s coefficient 0.918 –0.363 0.401 0.428 0.198 –0.667
P value ,0.001 0.017 0.008 0.004 0.204 ,0.001
Abbreviations: ATP, Adult Treatment Panel; HDL, high-density lipoprotein.
Table 2 characteristics of the patients with and without the metabolic syndrome (Met syn)
Variable Mean ± SD or n (%) of patients P value MetSyn vs without MetSyn
With MetSyn (n = 23) Without MetSyn (n = 20)
Waist (cm) 110 ± 10 91 ± 15 ,0.001
sagittal abdominal diameter (cm) 25.6 ± 3.3 20.4 ± 2.6 ,0.001
Visceral fat area (cm2) 263 ± 113 134 ± 53 ,0.001
number of ATP iii criteria 3.9 ± 0.7 1.3 ± 0.7 ,0.001
HDL-c (mg/dL) 39 ± 18 50 ± 15 0.007
Tg (mg/dL) 177 ± 81 102 ± 38 ,0.001
Fasting glucose (mg/dL) 127 ± 50 96 ± 8 0.001
Hypertension, n (%) 17 (74) 10 (50) 0.065
Diabetic, n (%) 10 (43) 0 (0) 0.001
Male, n (%) 19 (83) 16 (80) 0.83
Age 69 ± 7 69 ± 10 0.75
Fasting insulin (mU/L) 9.3 ± 4.9 4.9 ± 2.7 0.001
QUicK index of insulin sensitivity 0.242 ± 0.031 0.263 ± 0.26 0.001
Abbreviations: ATP, Adult Treatment Panel; HDL-c, high-density lipoprotein cholesterol; sD, standard deviation; Tg, triglycerides. 
dependent  variable, only waist circumference is retained 
in the model with an R2 of 0.79, P , 0.001. Hence, waist 
circumference is an important determinant of SAD but does 
not explain all the variation in SAD.
Discussion
This report is the second report to show that SAD is a stronger 
predictor of the metabolic syndrome than the current gold 
standard for assessing obesity-related cardiovascular risk, 
the VFA. Unlike VFA, SAD does not require imaging to be 
measured. An SAD value of .22.7 cm identified patients 
with the metabolic syndrome with a 91% sensitivity and 80% 
specificity. Patients with an SAD . 22.7 cm had significantly 
lower QUICK insulin sensitivity indices than patients with an 
SAD , 22.7 cm which is consistent with this threshold being 
able to identify insulin-resistant patients. SAD correlates 
with insulin sensitivity and all components of the metabolic 
syndrome except for hypertension. On multivariate regres-
sion, waist circumference is the only significant determinant 
of SAD (R2 of 0.79, P , 0.001).
The association of SAD with the metabolic syndrome 
is a clinically-significant one since the clinical label of 
‘metabolic syndrome’ in patients with established vas-
cular disease identifies a cohort at an increased risk of 
cardiovascular events.6–9 Hence, this measure of obesity 
can potentially identify a higher-risk cohort. While our 
data are  encouraging in showing that SAD may better 
identify the higher-risk patient than VFA, our data set is 
small and cross-sectional. A large prospective cohort is 
required to determine if SAD is independently associated 
with cardiovascular events. From a pragmatic perspective, 
such a measure would be preferable to VFA for quantify-
ing obesity-related cardiovascular risk since SAD can 
theoretically be measured in the office without requiring 
an imaging modality. However, clinic measurements of 
SAD using Holtain-Kahn calipers typically result in larger 
values than the MRI-measured SAD and would therefore 
require independent validation and adjustment for a predic-
tive cut-off value. Nevertheless, the conclusions reached 
from the MRI-derived SAD cannot be extended to caliper-
derived measurements without validation. In summary, we 
have shown MRI-measured SAD to be associated with the 
metabolic syndrome independently of VFA. SAD requires 
further validation as a maker of obesity-related cardiovas-
cular risk and assessment in prospective cohort studies. 
This measure could potentially replace waist circumference 
as the preferred office-based method of assessing obesity-
related cardiovascular risk.
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